Metropolitan Life Insurance Company (MetLife)’s Acadia Pharmaceuticals ACAD Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,624	Closed	-$122K	–	25
2024 Q1	$122K	Sell	6,624 -320	-5%	-$7.93K	0.01%	948
2023 Q4	$217K	Hold	6,944	–	–	0.01%	693
2023 Q3	$145K	Buy	6,944 +272	+4%	+$7.39K	0.01%	831
2023 Q2	$160K	Hold	6,672	–	–	0.01%	778
2023 Q1	$126K	Sell	6,672 -761	-10%	-$14.5K	0.01%	888
2022 Q4	$118K	Buy	7,433 +278	+4%	+$4.34K	0.01%	965
2022 Q3	$117K	Sell	7,155 -629	-8%	-$10.2K	0.01%	934
2022 Q2	$110K	Hold	7,784	–	–	﹤0.01%	1007
2022 Q1	$189K	Sell	7,784 -23,265	-75%	-$563K	0.01%	841
2021 Q4	$725K	Sell	31,049 -1,939	-6%	-$39K	0.01%	1179
2021 Q3	$548K	Hold	32,988	–	–	0.01%	1395
2021 Q2	$805K	Buy	32,988 +24,946	+310%	+$563K	0.01%	1172
2021 Q1	$207K	Sell	8,042 -362	-4%	-$15.9K	﹤0.01%	1997
2020 Q4	$449K	Sell	8,404 -163	-2%	-$8.09K	0.01%	1425
2020 Q3	$353K	Sell	8,567 -121	-1%	-$5.22K	0.01%	1439
2020 Q2	$421K	Sell	8,688 -25,006	-74%	-$1.2M	0.01%	1343
2020 Q1	$1.42M	Sell	33,694 -754	-2%	-$31.1K	0.03%	512
2019 Q4	$1.47M	Buy	34,448 +1,127	+3%	+$49K	0.02%	701
2019 Q3	$1.2M	Sell	33,321 -2,600	-7%	-$78.8K	0.02%	761
2019 Q2	$960K	Hold	35,921	–	–	0.02%	921
2019 Q1	$964K	Buy	35,921 +3,564	+11%	+$83.2K	0.02%	894
2018 Q4	$523K	Hold	32,357	–	–	0.01%	1168
2018 Q3	$672K	Hold	32,357	–	–	0.01%	1168
2018 Q2	$494K	Buy	32,357 +25,015	+341%	+$446K	0.01%	1321
2018 Q1	$165K	Buy	7,342 +1	+0%	+$28	﹤0.01%	2014
2017 Q4	$221K	Buy	7,341 +59	+0.8%	+$1.89K	﹤0.01%	1856
2017 Q3	$274K	Buy	7,282 +372	+5%	+$12.1K	﹤0.01%	2084
2017 Q2	$193K	Buy	6,910 +342	+5%	+$10.2K	﹤0.01%	2353
2017 Q1	$226K	Hold	6,568	–	–	﹤0.01%	2190
2016 Q4	$189K	Sell	6,568 -297	-4%	-$7.86K	﹤0.01%	2378
2016 Q3	$218K	Buy	6,865 +66	+1%	+$2.24K	﹤0.01%	2283
2016 Q2	$221K	Sell	6,799 -53,164	-89%	-$1.78M	﹤0.01%	2253
2016 Q1	$1.68M	Buy	59,963 +4,517	+8%	+$98.5K	0.01%	953
2015 Q4	$1.98M	Hold	55,446	–	–	0.02%	900
2015 Q3	$1.83M	Sell	55,446 -496	-0.9%	-$20.6K	0.01%	937
2015 Q2	$2.34M	Sell	55,942 -5,637	-9%	-$218K	0.02%	909
2015 Q1	$2.01M	Sell	61,579 -299	-0.5%	-$10.3K	0.01%	893
2014 Q4	$1.97M	Hold	61,878	–	–	0.01%	977
2014 Q3	$1.53M	Hold	61,878	–	–	0.01%	1045
2014 Q2	$1.4M	Hold	61,878	–	–	0.01%	1151
2014 Q1	$1.5M	Buy	61,878 +5,746	+10%	+$145K	0.01%	1106
2013 Q4	$1.4M	Hold	56,132	–	–	0.01%	1141
2013 Q3	$1.54M	Hold	56,132	–	–	0.01%	1059
2013 Q2	$1.02M	Buy	+56,132	New	+$773K	0.01%	1221

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ACAD Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 6,624 shares — an estimated $122K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ACAD in Q2 2013 and held it in 44 quarters. The position peaked at $2.34M in Q2 2015. 265 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 6,624 Acadia Pharmaceuticals shares in Q2 2024, an estimated $122K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 44 quarters.
Metropolitan Life Insurance Company (MetLife)'s Acadia Pharmaceuticals position peaked at $2.34M in Q2 2015.
265 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.